Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Preferred Stock Liabilities: 2023

  • Zenas BioPharma's Preferred Stock Liabilities was N/A to $250.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $250.1 million, marking a year-over-year change of. This contributed to the annual value of $250.1 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q4 2023, Zenas BioPharma's Preferred Stock Liabilities is $250.1 million, which was up 29.38% from $193.3 million recorded in Q3 2023.
  • Over the past 5 years, Zenas BioPharma's Preferred Stock Liabilities peaked at $250.1 million during Q4 2023, and registered a low of $193.3 million during Q3 2023.
  • Its 1-year average for Preferred Stock Liabilities is $221.7 million, with a median of $221.7 million in 2023.